MA31160B1 - Composé 3-substitue-[1,2,3]benzotriazinone pour améliorer les réponses synaptiques glutamatergiques. - Google Patents
Composé 3-substitue-[1,2,3]benzotriazinone pour améliorer les réponses synaptiques glutamatergiques.Info
- Publication number
- MA31160B1 MA31160B1 MA32135A MA32135A MA31160B1 MA 31160 B1 MA31160 B1 MA 31160B1 MA 32135 A MA32135 A MA 32135A MA 32135 A MA32135 A MA 32135A MA 31160 B1 MA31160 B1 MA 31160B1
- Authority
- MA
- Morocco
- Prior art keywords
- glutamerge
- benzotriazinone
- qualifies
- answers
- posture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention concerne la prévention et le traitement de l'insuffisance cérébrale, en particulier l'amélioration du fonctionnement de récepteur des synapses des réseaux cérébraux responsables de comportements d'ordre supérieur. Lesdits réseaux cérébraux sont impliqués dans des capacités cognitives en rapport avec un handicap de la mémoire observés dans un certain nombre de démences et dans des déséquilibres de l'activité neuronale entre différentes régions cérébrales ou supposés dans des troubles tels que la maladie de parkinson, la schizophrénie et les troubles affectifs. Selon un développement particulier, la présente invention concerne un composé utile dans le traitement de tels états et un procédé d'utilisation de ce composé dans un tel traitement.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87850307P | 2007-01-03 | 2007-01-03 | |
US92143307P | 2007-04-02 | 2007-04-02 | |
PCT/US2007/026416 WO2008085506A1 (fr) | 2007-01-03 | 2007-12-28 | Composé de [1,2,3]-benzotriazinone 3-substituée destiné à améliorer les réponses synaptiques glutamatergiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31160B1 true MA31160B1 (fr) | 2010-02-01 |
Family
ID=39608956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32135A MA31160B1 (fr) | 2007-01-03 | 2009-07-31 | Composé 3-substitue-[1,2,3]benzotriazinone pour améliorer les réponses synaptiques glutamatergiques. |
Country Status (38)
Country | Link |
---|---|
US (1) | US8173644B2 (fr) |
EP (1) | EP2144506B1 (fr) |
JP (1) | JP5139446B2 (fr) |
CN (1) | CN101616592B (fr) |
AP (1) | AP2502A (fr) |
AR (1) | AR064740A1 (fr) |
AT (1) | ATE527269T1 (fr) |
AU (1) | AU2007342365B2 (fr) |
BR (1) | BRPI0720749A2 (fr) |
CA (1) | CA2674460C (fr) |
CR (1) | CR10906A (fr) |
CU (1) | CU23804B7 (fr) |
CY (1) | CY1112493T1 (fr) |
DK (1) | DK2144506T3 (fr) |
EA (1) | EA017437B1 (fr) |
EC (1) | ECSP099499A (fr) |
ES (1) | ES2374995T3 (fr) |
GE (1) | GEP20125438B (fr) |
GT (1) | GT200900189A (fr) |
HK (1) | HK1140105A1 (fr) |
HN (1) | HN2009001268A (fr) |
HR (1) | HRP20110970T1 (fr) |
IL (1) | IL199651A (fr) |
MA (1) | MA31160B1 (fr) |
ME (1) | ME00819B (fr) |
MX (1) | MX2009007242A (fr) |
MY (1) | MY154877A (fr) |
NI (1) | NI200900131A (fr) |
NZ (1) | NZ578293A (fr) |
PL (1) | PL2144506T3 (fr) |
PT (1) | PT2144506E (fr) |
RS (1) | RS52108B (fr) |
SG (1) | SG163545A1 (fr) |
SI (1) | SI2144506T1 (fr) |
SV (1) | SV2009003322A (fr) |
TN (1) | TN2009000277A1 (fr) |
WO (1) | WO2008085506A1 (fr) |
ZA (1) | ZA200904826B (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007342364A1 (en) * | 2007-01-03 | 2008-07-17 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
US8013003B2 (en) | 2007-05-17 | 2011-09-06 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
SG163526A1 (en) | 2007-08-10 | 2010-08-30 | Cortex Pharma Inc | Bicyclic amides for enhancing glutamatergic synaptic responses |
US8119632B2 (en) | 2007-08-10 | 2012-02-21 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
US20110257186A1 (en) * | 2010-04-15 | 2011-10-20 | Staubli Ursula V | Compositions and methods for treating visual disorders |
EP2784065B1 (fr) | 2011-11-22 | 2016-10-05 | Beijing Medisan Technology Co. Ltd. | Inhibiteur de recaptage de glycine et son utilisation |
FR3019464B1 (fr) * | 2014-04-07 | 2016-05-06 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
FR3034019B1 (fr) * | 2015-03-26 | 2017-03-17 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent |
AU2016284654B9 (en) | 2015-06-26 | 2020-05-21 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor |
CN106226509B (zh) * | 2016-08-12 | 2019-09-06 | 中国人民解放军第四军医大学 | 一种在小鼠前扣带回皮层诱发dse现象的方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3723436A (en) | 1971-02-25 | 1973-03-27 | Sun Oil Co | Process for aromatic lactams |
DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
FR2597103B1 (fr) | 1986-04-15 | 1988-12-16 | Provesan Sa | Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde |
ATE215079T1 (de) | 1992-07-24 | 2002-04-15 | Univ California | Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen |
US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
DE59504622D1 (de) * | 1994-10-31 | 1999-02-04 | Merck Patent Gmbh | Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren |
US5650409A (en) | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
US5736543A (en) | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
US6030968A (en) | 1996-09-17 | 2000-02-29 | The Regents Of The University Of California | Positive AMPA receptor modulation to enhance brain neurotrophic factor expression |
US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
US5985871A (en) * | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
HUP0101280A3 (en) | 1998-02-18 | 2003-02-28 | Neurosearch As | Positive ampa receptor modulator compounds and their use |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
US6303542B1 (en) * | 2000-08-18 | 2001-10-16 | Rohm And Haas Company | Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones |
EA011034B1 (ru) * | 2001-11-26 | 2008-12-30 | Кортекс Фармасеутикалс, Инк. | Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов |
JP2003238555A (ja) * | 2002-02-20 | 2003-08-27 | Sumitomo Pharmaceut Co Ltd | 細胞死抑制剤 |
AUPS255202A0 (en) * | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with motor neuron degeneration |
KR20050094840A (ko) * | 2003-01-13 | 2005-09-28 | 코텍스 파마슈티칼스, 인크. | 수면 부족 및 스트레스로 인한 인식 저하의 치료방법 |
GB0317482D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
AU2007342364A1 (en) | 2007-01-03 | 2008-07-17 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
US8013003B2 (en) | 2007-05-17 | 2011-09-06 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
SG163526A1 (en) | 2007-08-10 | 2010-08-30 | Cortex Pharma Inc | Bicyclic amides for enhancing glutamatergic synaptic responses |
WO2009038752A2 (fr) * | 2007-09-20 | 2009-03-26 | Cortex Pharmaceuticals, Inc. | 1,2,3-triazine-4-ones 3-substituées et 1,3-pyrimidinones 3-substituées pour améliorer les réponses synaptiques glutamatergiques |
-
2007
- 2007-12-28 SG SG201004695-1A patent/SG163545A1/en unknown
- 2007-12-28 PL PL07868093T patent/PL2144506T3/pl unknown
- 2007-12-28 MX MX2009007242A patent/MX2009007242A/es active IP Right Grant
- 2007-12-28 DK DK07868093.1T patent/DK2144506T3/da active
- 2007-12-28 US US12/448,784 patent/US8173644B2/en active Active
- 2007-12-28 AU AU2007342365A patent/AU2007342365B2/en not_active Ceased
- 2007-12-28 MY MYPI20092796A patent/MY154877A/en unknown
- 2007-12-28 RS RS20110587A patent/RS52108B/en unknown
- 2007-12-28 SI SI200730806T patent/SI2144506T1/sl unknown
- 2007-12-28 NZ NZ578293A patent/NZ578293A/en not_active IP Right Cessation
- 2007-12-28 CN CN2007800508375A patent/CN101616592B/zh not_active Expired - Fee Related
- 2007-12-28 EP EP07868093A patent/EP2144506B1/fr active Active
- 2007-12-28 CA CA2674460A patent/CA2674460C/fr not_active Expired - Fee Related
- 2007-12-28 PT PT07868093T patent/PT2144506E/pt unknown
- 2007-12-28 EA EA200900925A patent/EA017437B1/ru not_active IP Right Cessation
- 2007-12-28 AT AT07868093T patent/ATE527269T1/de active
- 2007-12-28 GE GEAP200711384A patent/GEP20125438B/en unknown
- 2007-12-28 WO PCT/US2007/026416 patent/WO2008085506A1/fr active Application Filing
- 2007-12-28 ME MEP-2009-238A patent/ME00819B/fr unknown
- 2007-12-28 JP JP2009544857A patent/JP5139446B2/ja not_active Expired - Fee Related
- 2007-12-28 ES ES07868093T patent/ES2374995T3/es active Active
- 2007-12-28 BR BRPI0720749-2A patent/BRPI0720749A2/pt not_active Application Discontinuation
- 2007-12-28 ZA ZA200904826A patent/ZA200904826B/xx unknown
- 2007-12-28 AP AP2009004931A patent/AP2502A/xx active
-
2008
- 2008-01-03 AR ARP080100022A patent/AR064740A1/es not_active Application Discontinuation
-
2009
- 2009-06-30 TN TNP2009000277A patent/TN2009000277A1/fr unknown
- 2009-07-01 NI NI200900131A patent/NI200900131A/es unknown
- 2009-07-02 SV SV2009003322A patent/SV2009003322A/es unknown
- 2009-07-02 IL IL199651A patent/IL199651A/en active IP Right Grant
- 2009-07-02 GT GT200900189A patent/GT200900189A/es unknown
- 2009-07-02 CR CR10906A patent/CR10906A/es not_active Application Discontinuation
- 2009-07-03 CU CU20090117A patent/CU23804B7/es active IP Right Grant
- 2009-07-03 HN HN2009001268A patent/HN2009001268A/es unknown
- 2009-07-07 EC EC2009009499A patent/ECSP099499A/es unknown
- 2009-07-31 MA MA32135A patent/MA31160B1/fr unknown
-
2010
- 2010-06-29 HK HK10106349.3A patent/HK1140105A1/xx not_active IP Right Cessation
-
2011
- 2011-12-23 HR HR20110970T patent/HRP20110970T1/hr unknown
- 2011-12-28 CY CY20111101287T patent/CY1112493T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31160B1 (fr) | Composé 3-substitue-[1,2,3]benzotriazinone pour améliorer les réponses synaptiques glutamatergiques. | |
MA31159B1 (fr) | Composés [1,2,3]benzotriazinone substitués en position 3 destinés à améliorer les réponses synaptiques glutamatergiques | |
Liu et al. | The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia | |
Malykh et al. | Piracetam and piracetam-like drugs | |
NO20064726L (no) | Imidazolforbindelser for behandling av neurodegenerative forstyrrelser | |
MA34922B1 (fr) | Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques | |
TN2014000424A1 (fr) | Agents pour le traitement de troubles impliquant la modulation des recepteurs de la ryanodine | |
MA34898B1 (fr) | Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques | |
MY148558A (en) | Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use | |
US20120171125A1 (en) | Methods for Enhancing the Cognitive Function | |
MA32374B1 (fr) | Composes comprenant un groupe cyclobutoxy | |
JP2009537568A5 (fr) | ||
WO2007034326A3 (fr) | Composes imidazoles pour le traitement de troubles neurologiques | |
WO2005095348A3 (fr) | Composes pyrazole-amines utilises dans le traitement des troubles neurodegeneratifs | |
GEP20063859B (en) | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | |
MA30661B1 (fr) | Derives de n-phenyl-prenylamine pour le traitement de maladies ou troubles cognitifs, neurodegeneratifs ou neuronaux. | |
MA29806B1 (fr) | Derives de 2-aminothiazoles et 2- aminooxazoles,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques | |
UA93306C2 (ru) | Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций | |
Seeman et al. | Schizophrenia and the supersensitive synapse | |
Bassett | Cognitive impairment | |
CAZZULLO | COGNITIVE IMPAIRMENT IN PHYSIOLOGICAL AND PATHOLOGICAL AGING | |
TH117332A (fr) | ||
TH86961A (th) | สารรักษาโรค |